Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
SAN ANTONIO – Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
Breast MRI is commonly included as part of the diagnostic workup of breast cancer ...